Lightnews — Scholar-powered news

David Aggen, MD @davidaggen.bsky.social · Apr 25

If you are looking for updates in #GU, join us in NYC on 4/30 for @OncLive #Stateofthescience summit. Free for healthcare professionals to register here!

shorturl.at/uTCUA

David Aggen, MD @davidaggen.bsky.social · Feb 15

Very proud of rising star fellow Aditi Gupta for her work on immune profiling in mUC patients receiving EV #ASCOGU @MSKCancerCenter #GU25

1 4

David Aggen, MD @davidaggen.bsky.social · Feb 15

Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with

ORR of 41%
DCR 90%
50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor

@MSKCancerCenter #ASCOGU #GU25

2 3

David Aggen, MD @davidaggen.bsky.social · Feb 14

Excited to hear a review of the DV + PD-1 from our MSK Cancer Center colleague Scot Niglio #ASCOGU #GU25

Path Cr rate of 84.6% in HER2 3+

1 2

Reposted by David Aggen, MD

Tian Zhang, MD @tiansterzhangmd.bsky.social · Feb 14

#MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing #Alliance #MODERN trial! @ascocancer.bsky.social #GU25

4 6

David Aggen, MD @davidaggen.bsky.social · Feb 13

Congrats to Vinod Balachandran, a surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK, for being named to the inaugural edition of the @washingtonpost's Next 50, a list of up-and-coming changemakers shaping society in 2025.

bit.ly/3CMJhN6

Memorial Sloan Kettering Cancer Center Surgeon-Scientist, Vinod Balachandran, MD, Named to The Washington Post Next 50

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce The Washington Post has named Vinod Balachandran, MD, surgeon-scientist and Director of The Olayan Center for Cancer Vaccines at MSK...

bit.ly

Reposted by David Aggen, MD

Toni Choueiri, MD @drchoueiri.bsky.social · Feb 5

Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer

www.nature.com/articles/s41...

This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab

www.nature.com/articles/s41...

1 15 28

Reposted by David Aggen, MD

Esther Choo @choo.bsky.social · Jan 24

An explainer about how health research funding happens and why this NIH funding cycle shutdown matters: www.msnbc.com/opinion/msnb...

Opinion | I’m a health researcher. NIH’s pause on research grants could have a devastating cost.

This is a potentially devastating event — not just for the scientific community, but for all Americans.

www.msnbc.com

16 270 510

David Aggen, MD @davidaggen.bsky.social · Jan 24

Gopa Iyer discussing the potential for platinum following EV + pembro for advanced UC #AUC3 #bladdercancer

1 2

David Aggen, MD @davidaggen.bsky.social · Jan 24

Reposted by David Aggen, MD

Tian Zhang, MD @tiansterzhangmd.bsky.social · Jan 24

This GU oncology family — wonderful first #AUC3 consensus conference!
@drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social

3 8

David Aggen, MD @davidaggen.bsky.social · Jan 24

At #AUC3 this A.M. discussing what’s next for treatment of NMIBC and treatment of variant histology UC - Gopa Iyer and Josh Meeks chairing session this AM with talks from Andrea Necchi, Michiel Van der Heijden, and Roger Li #bladdercancer

1 1 3

David Aggen, MD @davidaggen.bsky.social · Jan 23

Dr. Marie Carlo discussing the role of NGS and germline testing for RCC and non-clear cell RCC @MSKCancerCenter #auc3 #kidneycancer @BradMcG04 chairing session

1

David Aggen, MD @davidaggen.bsky.social · Jan 23

Dr. Motzer reviewing the treatment landscape for advanced kidney cancer. Discussing when is the right time to introduce belzutifan. @MSKCancerCenter #AUC3 #kidneycancer

David Aggen, MD @davidaggen.bsky.social · Jan 23

Stellar overview of cytoreductive nephrectomy in the era of combination immunotherapy by Ari Hakimi #auc3 #kidneycancer

1

Reposted by David Aggen, MD

Gregory Riely @rielymd.bsky.social · Dec 4

As we explore more and more HLA-specific immune based therapies, this from MSK in JAMA Onc shows that standard NGS testing can infer HLA genotypes. Other NGS providers have done/can do @adamjschoenfeld.bsky.social @mskcancercenter.bsky.social @davidaggen.bsky.social jamanetwork.com/journals/jam...

Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies

This case series evaluates whether human leukocyte antigen (HLA) genotype could be inferred from standard next-generation sequencing, comparing concordance with confirmatory whole-exome sequencing and...

jamanetwork.com

5 10

Reposted by David Aggen, MD

Jame Abraham, MD, FACP @jameabraham.bsky.social · Jan 4

Surgeon General Calls for Cancer Warnings on Alcohol www.nytimes.com/2025/01/03/h... I think American Cancer Society and @ascocancer.bsky.social @jrgralow.bsky.social should support this initiative @oncoalert.bsky.social

U.S. Surgeon General Calls for Cancer Warnings on Alcohol

Dr. Vivek Murthy’s report cites studies linking alcoholic beverages to at least seven malignancies, including breast cancer. But to add warning labels, Congress would have to act.

www.nytimes.com

3 8

David Aggen, MD @davidaggen.bsky.social · Dec 13

Innovative therapies in GU cancers: Promising targets in #Urothelial and #Kidney cancer.- BL-B01D1: A bispecific ADC (EGFR/HER3) with a 40% response rate in advanced urothelial cancer.
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe

Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg

Alicia Morgans speaks with Jonathan Rosenberg about two novel therapies presented at ESMO 2024. The discussion centers on BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in adva...

bit.ly

4

Reposted by David Aggen, MD

Nima Sharifi MD @nimasharifimd.bsky.social · Dec 11

My heart sank when I heard the news that Felix Feng has passed away. Felix was such a gentle and uplifting force for so many of us who work in the same field - and for anyone he touched. Although he has left us, his impact will be felt forever. ow.ly/Uc3H50TSBiC

I just helped save a life

You can save one, too. Donate now.

ow.ly

2 8 26

Reposted by David Aggen, MD

Laura Caba @lauracaba.bsky.social · Dec 4

Rich Matulewicz #SUO24

“Blockbuster New Therapy for Cancer…. Smoking Cessation “.

@joshmeeks.bsky.social
@yawnyame.bsky.social
@wandering-gu.bsky.social

7 11

David Aggen, MD @davidaggen.bsky.social · Dec 4

#SUO24 Implementing Smoking Cessation in the Urologic Oncology Setting @RichMatulewicz

Urologists: the most trusted and utilized source of information regarding the cause and 🚬-related nature of the patient’s bladder ca diagnosis

@urotoday

2

David Aggen, MD @davidaggen.bsky.social · Dec 4

@RichMatulewicz representing @UrologyMSK at the #SUO24 discussing clinical evolution in the management of seminoma.

3

Reposted by David Aggen, MD

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · Nov 27

AI has a huge potential in #BladderCancer for diagnosis, prognostic and predictive assessment
Some questions remain to be answered related to:
▶️ Heterogeneity of disease
▶️ Interreader variability of pathology assessment
▶️ Which ground truth to apply? #AI #MachineLearning @oncoalert.bsky.social

The OncoAlert Network 🚨 @oncoalert.bsky.social · Nov 27

Day One of #BLADDR24
Dr Eva Maria Compérat
Role of AI for diagnosis and monitoring #BladderCancer

Emphasizes the broad potential of AI in diagnosing and monitoring

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

5 9

David Aggen, MD @davidaggen.bsky.social · Nov 26

We are excited to enroll patients with LN + bladder cancer on our neoadjuvant enfortumab vedotin + pembrolizumab trial @mskcc.bsky.sm

Now enrolling patients with N1-N3 disease #BLCSM

6 Cycles EV + P -> Cystectomy -> Pembrolizumab

www.mskcc.org/cancer-care/...

A Phase II Study of Enfortumab Vedotin and Pembrolizumab Immunotherapy Given Before Surgery in People with Bladder Cancer

Full Title Enfortumab Vedotin in Combination with Pembrolizumab for Locally Advanced and/or Node Positive Urothelial Carcinoma Prior to Surgery (EV-ECLIPSE) Purpose Researchers in this study are asses...

www.mskcc.org

2

David Aggen, MD @davidaggen.bsky.social · Nov 26

We are actively enrolling patients with high risk bladder cancer on a trial evaluating a personalized mRNA neoantigen vaccine following bladder surgery. @mskcc.bsky.social #blcsm #bladdercancer www.mskcc.org/cancer-care/...

A Phase 2 Study of Autogene Cevumeran Plus Nivolumab Immunotherapy Versus Nivolumab Alone in People With Muscle-Invasive Bladder Cancer

Full Title A Randomized Phase II, Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients with High-Ris...

www.mskcc.org

1 4